Across TCGA pan-cancer cohorts, UBE2D2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated UBE2D2 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher UBE2D2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2D2 expression acts as an unfavorable survival marker.
ESCA are the cancer types where UBE2D2 Mutation most reproducibly stratifies survival.